株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Onconova Therapeutics, Inc. の製品パイプライン分析

Onconova Therapeutics, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 219811
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
Onconova Therapeutics, Inc. の製品パイプライン分析 Onconova Therapeutics, Inc. - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 50 Pages
概要

Onconova Therapeutics, Inc. は米国に本社を置くバイオ製薬企業で、特許をもつ化学的プラットフォームを利用して抗癌治療薬の標的ライブラリを作成し、癌治療のための新たな小分子薬候補物質の開発を行っています。

当レポートでは、Onconova Therapeutics, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Onconova Therapeutics, Inc. の基本情報

  • Onconova Therapeutics, Inc. の概要
  • 主要情報
  • 企業情報

Onconova Therapeutics, Inc. :R&Dの概要

  • 主な治療範囲

Onconova Therapeutics, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Onconova Therapeutics, Inc. :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Onconova Therapeutics, Inc. :薬剤プロファイル

  • rigosertib sodium
  • briciclib sodium
  • recilisib sodium
  • ON-012380
  • ON-015640
  • ON-044580
  • ON-108600
  • ON-1231320
  • ON-123300
  • ON-146040
  • ON-24 Series
  • ON-24160
  • ON-108110
  • ON-128060

Onconova Therapeutics, Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Onconova Therapeutics, Inc. :最新のパイプライン情報

Onconova Therapeutics, Inc. :開発休止中のプロジェクト

Onconova Therapeutics, Inc. :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07411CDB

Summary

Global Markets Direct's, 'Onconova Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Onconova Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Onconova Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Onconova Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Onconova Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Onconova Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Onconova Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Onconova Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Onconova Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Onconova Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Onconova Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Onconova Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Onconova Therapeutics, Inc. Snapshot
    • Onconova Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Onconova Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Onconova Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Onconova Therapeutics, Inc. - Pipeline Products Glance
    • Onconova Therapeutics, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Onconova Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Onconova Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Onconova Therapeutics, Inc. - Drug Profiles
    • rigosertib sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • briciclib sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • recilisib sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ON-015640
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ON-108600
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ON-1231320
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ON-123300
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ON-146040
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ON-24 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ON-24160
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ON-108110
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ON-128060
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Onconova Therapeutics, Inc. - Pipeline Analysis
    • Onconova Therapeutics, Inc. - Pipeline Products by Target
    • Onconova Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Onconova Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Onconova Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Onconova Therapeutics, Inc. - Recent Pipeline Updates
  • Onconova Therapeutics, Inc. - Dormant Projects
  • Onconova Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • rigosertib sodium
  • Onconova Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Onconova Therapeutics, Inc., Key Information
  • Onconova Therapeutics, Inc., Key Facts
  • Onconova Therapeutics, Inc. - Pipeline by Indication, 2015
  • Onconova Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Onconova Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Onconova Therapeutics, Inc. - Phase III, 2015
  • Onconova Therapeutics, Inc. - Phase II, 2015
  • Onconova Therapeutics, Inc. - Phase I, 2015
  • Onconova Therapeutics, Inc. - Preclinical, 2015
  • Onconova Therapeutics, Inc. - Discovery, 2015
  • Onconova Therapeutics, Inc. - Pipeline by Target, 2015
  • Onconova Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Onconova Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Onconova Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Onconova Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Onconova Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Onconova Therapeutics, Inc. - Discontinued Pipeline Products, 2015
  • Onconova Therapeutics, Inc., Other Locations

List of Figures

  • Onconova Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Onconova Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Onconova Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Onconova Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Onconova Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Onconova Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Onconova Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top